ERBB2 and breast carcinoma: After overexpressing M6PR in HER2-positive breast cancer cells, the number of living cells was calculated using a CCK8 kit, and the results showed that M6PR overexpression in HCC1954 and JIMT-1 increased the sensitivity of breast cancer cells to pyrotinib (Figure 5d,e).